Visara

Company

Visara develops one asset, in phase 1 (HT006.2.2 in neurotrophic keratitis). Mostly protein or enzyme acting on NTRK1.

1
Asset
Furthest stage
Phase 1
0
Trials
2
Signals

Pipeline

1
  • HT006.2.2

    NGF eye drops promote corneal nerve survival and repair.

    Phase 1, Protein or enzyme, NTRK1, neurotrophic keratitis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Signals2

Intelligence